

Global Alzheimer's Platform Foundation. Review of 75 Drugs Covered by CMS.

| Accelerated Approval Date | Drug | Lead Sponsor | Therapeutic Area | Indication | Link to label at time of initial approval | Black Box Warning | Risk Evaluation and Mitigation Strategy (REMS) | Orphan Drug Designation | Estimated Patient Population* | Date of CMS NCD | Pricing (annual or Tx duration WAC as of Feb 2022) |
|---------------------------|--|-------------------------|--------------------|---|---|--|--|-------------------------|--|--|--|
| 12/2021 | Tarpeyo (budenoside) | Calliditas Therapeutics | Renal | Immunoglobulin A Nephropathy (Berger's Disease) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215935s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$127,440.00 |
| 10/2021 | Scemblix (asciminib) | Novartis | Oncology | Chronic Myelogenous Leukemia | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig2lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$217,783.34 |
| 9/2021 | Tivdak (tisotumab vedotin-tftv) | Seagen | Oncology | Cervical Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208Orig1s000lbl.pdf | Black Box Warning for "OCULAR TOXICITY" | N/A | No | 293,394 (women with cervical cancer in the US in 2018) | Does not apply | \$358,004.17 |
| 9/2021 | Exkivity (mobicertinib) | Takeda | Oncology | Non-Small Cell Lung Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf | Black Box Warning for "QTc PROLONGATION AND TORSADES DE POINTES" | N/A | Yes | <200000 | Does not apply | \$304,166.65 |
| 6/2021 | Aduhelm (aducanumab) | Biogen | Neurology | Alzheimer's Disease | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf | N/A | N/A | No | 1-2 million (patients with MCI and mild AD in the US) | Does not apply | \$28,200.00 |
| 5/2021 | Lumkras (sotorasib) | Amgen | Oncology | Non-Small Cell Lung Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$224,316.97 |
| 5/2021 | Truseltiq (infigratinib) | BridgeBio Pharma | Oncology | Biliary Tract Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$280,267.85 |
| 5/2021 | Rybrevant (amivantamab-vmjw) | Johnson & Johnson | Oncology | Non-Small Cell Lung Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf | N/A | N/A | No | 582,631 (people with lung and bronchus cancer in the US in 2018; 85% of them have NSCLC) | Does not apply | \$265,081.32 |
| 4/2021 | Zynlonta (loncastuximab tesirine-lpyl) | ADC Therapeutics | Oncology | Diffuse Large B-Cell Lymphoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$239,112.50 |
| 4/2021 | Jemperli (dostarlimab-gxly) | GlaxoSmithKline | Oncology | Uterine Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf | N/A | N/A | No | 813,861 (women with uterine cancer in the US in 2018) | Does not apply | \$184,735.36 |
| 2/2021 | Amondys 45 (casimersen) | Sarepta | Neurology | Duchenne Muscular Dystrophy | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213026lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$1,001,142.86 |
| 2/2021 | Ukoniq (umbralisib) | TG Therapeutics | Oncology | Non-Hodgkin lymphoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$193,450.00 |
| 11/2020 | Danyelza (naxitamab-gqgk) | Y-mAbs Therapeutics | Oncology | Neuroendocrine Tumors | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf | Black Box Warning for "SERIOUS INFUSION-RELATED REACTIONS and NEUROTOXICITY" | N/A | Yes | <200000 | Does not apply | \$2,257,254.05 |
| 9/2020 | Gavreto (pralsetinib) | Blueprint Medicines | Oncology | Non-Small Cell Lung Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213721Orig1s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$241,149.37 |
| 8/2020 | Viltepso (viltolarsen) | Nippon Shinyaku | Neurology | Duchenne Muscular Dystrophy | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212154Orig1s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$1,646,880.00 |
| 8/2020 | Lampit (nifurtimox) | Bayer | Infectious Disease | Chagas disease | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213464s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$1,050.00 |
| 8/2020 | Blenrep (belantamab mafodotin-blmf) | GlaxoSmithKline | Oncology | Multiple Myeloma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf | Black Box Warning for OCULAR TOXICITY | REMS for "ocular toxicity" | Yes | <200000 | Does not apply | \$261,923.70 |
| 7/2020 | Monjuvi (tafasitamab-cxix) | MorphoSys | Oncology | Diffuse Large B-Cell Lymphoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761163s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$135,371.56 |
| 7/2020 | Tecartus (brexucabtagene autoleucel) | Gilead Sciences | Oncology | Mantle Cell Lymphoma | https://www.fda.gov/media/141164/download | Black Box Warning for "CYTOKINE RELEASE SYNDROME AND NEUROLOGIC TOXICITIES" | REMS for "cytokine release syndrome (CRS) and neurological toxicities" | Yes | <200000 | NCD exists - coverage for FDA approved CAR-Ts granted on 08/07/2019 - Tecartus had coverage at launch. | \$399,000.00 |
| 6/2020 | Zepzelca (lurbinectedin) | Jazz Pharmaceuticals | Oncology | Small Cell Lung Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$169,228.60 |
| 5/2020 | Retevmo (selpercatinib) | Eli Lilly | Oncology | Non-Small Cell Lung Cancer and Thyroid Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$250,633.29 |
| 5/2020 | Tabrecta (capmatinib) | Novartis | Oncology | Non-Small Cell Lung Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$260,437.87 |

| | | | | | | | | | | |
|--|---------------------------|--------------------|---------------------------------|---|---|--|-----|--|----------------|----------------|
| Trdelvly (sacituzumab 4/2020 govitecan-hziy) | Gilead Sciences | Oncology | Breast Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf | Black Box Warning for "NEUTROPENIA AND DIARRHEA" | N/A | No | 3,676,262 (women with breast cancer in the US in 2018; 10% of them have TNBC) | Does not apply | \$295,846.03 |
| 4/2020 Pemazyre (pemigatinib) | Incyte | Oncology | Biliary Tract Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$304,340.48 |
| 1/2020 Tazverik (tazemetostat) | Epizyme | Oncology | Sarcoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213723s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$201,784.26 |
| Enhertu (fam-trastuzumab 12/2019 deruxtecan-nxki) | Daiichi Sankyo | Oncology | Breast Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf | Black Box Warning for "INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY" | N/A | No | 3,676,262 (women with breast cancer in the US in 2018; 14% of them have HER2+ BC) | Does not apply | \$159,289.65 |
| Padcev (enfortumab 12/2019 vedotin-ejfv) | Astellas Pharma | Oncology | Bladder Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf | N/A | N/A | No | 723,745 (people living with bladder cancer in the US in 2018) | Does not apply | \$404,636.72 |
| 12/2019 Vyondys 53 (golodirsen) | Sarepta | Neurology | Duchenne Muscular Dystrophy | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211970s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$1,752,000.00 |
| 11/2019 Oxbrtya (voxelotor) | Global Blood Therapeutics | Hematology | Sickle Cell Anemia | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$211,233.71 |
| 11/2019 Brukinsa (zanubrutinib) | BeiGene | Oncology | Mantle Cell Lymphoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$164,140.44 |
| 8/2019 Rozlytrek (entrectinib) | Roche Holding | Oncology | Solid Tumors | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$216,847.89 |
| 7/2019 Xpovio (selinexor) | Karyopharm Therapeutics | Oncology | Multiple Myeloma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212306s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$201,002.56 |
| Polivy (polatuzumab 6/2019 vedotin-piig) | Roche Holding | Oncology | Diffuse Large B-Cell Lymphoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/261121s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$100,285.80 |
| 4/2019 Balversa (erdafitinib) | Johnson & Johnson | Oncology | Bladder Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf | N/A | N/A | No | 723,745 (people living with bladder cancer in the US in 2018) | Does not apply | \$303,349.68 |
| 11/2018 Vitravici (larotrectinib) | Bayer | Oncology | Solid Tumors | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$411,041.10 |
| 11/2018 Lorbrena (lorlatinib) | Pfizer | Oncology | Non-Small Cell Lung Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$227,213.85 |
| 9/2018 Arikayce (amikacin) | Insmed | Infectious Disease | Respiratory Tract Infections | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207356s000lbl.pdf | Black Box Warning for "RISK OF INCREASED RESPIRATORY ADVERSE REACTIONS" | N/A | Yes | <200000 | Does not apply | \$174,316.35 |
| 9/2018 Copiktra (duvelisib) | Secura Bio | Oncology | Indolent Non-Hodgkin's Lymphoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf | Black Box Warning for FATAL AND SERIOUS TOXICITIES: INFECTIONS, DIARRHEA OR COLITIS, CUTANEOUS REACTIONS, and PNEUMONITIS | REMS for "infections, diarrhea or colitis, cutaneous reactions, and pneumonitis" | Yes | <200000 | Does not apply | \$214,387.31 |
| Galafold (migalastat 8/2018 hydrochloride) | Amicus Therapeutics | Metabolic | Fabry's Disease | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208623lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$342,904.46 |
| 5/2018 Andexxa (andexanet alfa) | AstraZeneca | Cardiovascular | Reversal of anticoagulation | https://www.fda.gov/media/13983/download | Black Box Warning for "THROMBOEMBOLIC RISKS, ISCHEMIC RISKS, CARDIAC ARREST, AND SUDDEN DEATHS" | N/A | Yes | <200000 | Does not apply | \$24,000.00 |
| 10/2017 Calquence (acalabrutinib) | AstraZeneca | Oncology | Mantle Cell Lymphoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$173,678.68 |
| 9/2017 Aliqopa (copanlisib) | Bayer | Oncology | Indolent Non-Hodgkin's Lymphoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$189,802.62 |
| Benznidazole 8/2017 (benznidazole) | Insud Pharma | Infectious Disease | Chagas disease | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209570lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$360.00 |
| 5/2017 Imfinzi (durvalumab) | AstraZeneca | Oncology | Bladder Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf | N/A | N/A | No | 582,631 (people with lung and bronchus cancer in the US in 2018; 85% of them have NSCLC) | Does not apply | \$158,987.31 |
| 4/2017 Alunbrig (brigatinib) | Takeda | Oncology | Non-Small Cell Lung Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$217,418.32 |

| | | | | | | | | | | | | |
|---------|---|---------------------------|--|---|---|--|-----|---|--|----------------|----------------|--------------|
| 3/2017 | Bavencio (avelumab) | Merck KGaA | Oncology | Merkel Cell Carcinoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$180,218.23 | |
| 12/2016 | Rubraca (rucaparib) | Clovis Oncology | Oncology | Ovarian Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$211,335.00 | |
| 9/2016 | Exondys 51 (eteplirsen) | Sarepta | Neurology | Duchenne Muscular Dystrophy | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206488bl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$1,752,000.00 | |
| 5/2016 | Ocaliva (obeticholic acid) | Intercept Pharmaceuticals | Autoimmune/immunology and Hepatic Fibrosis | Primary Biliary Cholangitis | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$97,874.87 | |
| 5/2016 | Tecentriq (atezolizumab) | Roche Holding | Oncology | Bladder Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034Orig1s000lbl.pdf | N/A | N/A | No | 723,745 (people living with bladder cancer in the US in 2018 - pulled indication); 149,956 (people living with MM in the US in 2018) | Does not apply | \$179,737.72 | |
| 4/2016 | Venclexta (venetoclax) | AbbVie | Oncology | Chronic Lymphocytic Leukemia /Small Cell Lymphocytic Lymphoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$160,170.00 | |
| 12/2015 | Alecensa (alelectinib) | Roche Holding | Oncology | Non-Small Cell Lung Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$200,649.99 | |
| 11/2015 | Darzalex (daratumumab) | Johnson & Johnson | Oncology | Multiple Myeloma | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/761036Orig1s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$158,359.76 | |
| 11/2015 | Tagrisso (osimertinib) | AstraZeneca | Oncology | Non-Small Cell Lung Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$185,036.38 | |
| 10/2015 | Praxbind (idarucizumab) | Boehringer Ingelheim | Cardiovascular | Reversal of anticoagulation | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/2761025lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$4,450.43 | |
| 2/2015 | Farydak (panobinostat lactate) | Secura Bio | Oncology | Multiple Myeloma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf | Black Box Warning for "SEVERE DIARRHEA AND CARDIAC TOXICITIES" | | REMS for "Severe diarrhea, Severe and fatal cardiac ischemic events, Severe arrhythmias, ECG changes" | Yes | <200000 | Does not apply | \$225,320.16 |
| 2/2015 | Ibrance (palbociclib) | Pfizer | Oncology | Breast Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf | N/A | N/A | No | 3,676,262 (women with breast cancer in the US in 2018; 68% of them have HR+/HER2- BC) | Does not apply | \$182,158.45 | |
| 1/2015 | Bexsero (Multicomponent meningococcal serogroup B vaccine) | GlaxoSmithKline | Infectious Disease | Meningococcal Vaccine | https://www.fda.gov/media/90996/download | N/A | N/A | No | Preventative | Does not apply | \$383.50 | |
| 12/2014 | Opdivo (nivolumab) | Bristol Myers Squibb | Oncology | Melanoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125527s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$180,282.05 | |
| 12/2014 | Lynparza (olaparib) | AstraZeneca | Oncology | Ovarian Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/208558s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$181,068.76 | |
| 12/2014 | Blinicyto (blinatumomab) | Amgen | Oncology | Acute Lymphoblastic Leukemia | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125557lbl.pdf | Black Box Warning for "CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES" | | REMS for "cytokine release syndrome, neurologic toxicity, and preparation/administration errors" | Yes | <200000 | Does not apply | \$402,517.25 |
| 10/2014 | Trumenba (Bivalent recombinant meningococcal serogroup B vaccine) | Pfizer | Infectious Disease | Meningococcal Vaccine | https://www.fda.gov/media/106751/download | N/A | N/A | No | Preventative | Does not apply | \$336.31 | |
| 9/2014 | Keytruda (pembrolizumab) | Merck | Oncology | Melanoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$178,480.13 | |
| 7/2014 | Zydelig (idelalisib) | Gilead Sciences | Oncology | Indolent Non-Hodgkin's Lymphoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf | Black Box Warning for "HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and INTESTINAL PERFORATION" | | REMS for "hepatotoxicity, severe diarrhea or colitis, pneumonitis, and intestinal perforation" | Yes | <200000 | Does not apply | \$151,229.57 |
| 7/2014 | Beleodaq (belinostat (IV)) | Aurobindo Pharma Limited | Oncology | Peripheral T-Cell Lymphoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$374,669.02 | |
| 4/2014 | Zykadia (ceritinib) | Novartis | Oncology | Non-Small Cell Lung Cancer | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755s000lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$144,434.22 | |

| | | | | | | | | | | | |
|---------|-------------------------------------|----------------------|--------------------|---|---|---|---------------------------|-----|---------|----------------|--------------|
| 2/2014 | Northera (droxidopa) | Lundbeck | Cardiovascular | Orthostatic Hypotension | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203202lbl.pdf | Black Box Warning for "SUPINE HYPERTENSION" | N/A | Yes | <200000 | Does not apply | \$3,003.82 |
| 11/2013 | Imbruvica (ibrutinib) | AbbVie | Oncology | Mantle Cell Lymphoma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205552Orig1s2lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$259,950.81 |
| 2/2013 | Pomalyst (pomalidomide) | Bristol Myers Squibb | Oncology | Multiple Myeloma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdf | Black Box Warning for "EMBRYO-FETAL TOXICITY and VENOUS THROMBOEMBOLISM" | REMS for "teratogenicity" | Yes | <200000 | Does not apply | \$259,638.46 |
| 12/2012 | Sirturo (bedaquiline) | Johnson & Johnson | Infectious Disease | Tuberculosis | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf | Black Box Warning for "increased risk of death" and "QT prolongation" | N/A | Yes | <200000 | Does not apply | \$30,000.01 |
| 12/2012 | Iclusig (ponatinib) | Takeda | Oncology | Acute Lymphoblastic Leukemia and Chronic Myelogenous Leukemia | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf | Black Box Warning for "ARTERIAL THROMBOSIS and HEPATOTOXICITY" | N/A | Yes | <200000 | Does not apply | \$228,842.83 |
| 10/2012 | Synribo (omacetaxine mepesuccinate) | Teva | Oncology | Chronic Myelogenous Leukemia | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$147,693.96 |
| 8/2012 | Marqibo (vincristine sulfate) | Aurobindo Pharma | Oncology | Acute Lymphoblastic Leukemia | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202497s000lbl.pdf | Black Box Warning for "For Intravenous Use Only – Fatal if Given by Other Routes" | N/A | Yes | <200000 | Does not apply | \$698,068.92 |
| 7/2012 | Kyprolis (carfilzomib) | Amgen | Oncology | Multiple Myeloma | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf | N/A | N/A | Yes | <200000 | Does not apply | \$160,768.64 |